Today: 20 March 2026
RELX share price: what to watch after Friday’s dip and a fresh buyback filing
17 January 2026
1 min read

RELX share price: what to watch after Friday’s dip and a fresh buyback filing

London, Jan 17, 2026, 08:00 GMT — The market has closed.

  • RELX closed Friday 0.93% lower, at 3,094 pence.
  • A company filing revealed another day of share buybacks for its treasury.
  • Next up: share admission under an employee plan on Jan. 20; full-year results set for Feb. 12.

RELX (REL.L) ended the week on a down note, slipping 0.93% to 3,094 pence Friday. The stock fluctuated between 3,070 and 3,122 pence, with roughly 6.9 million shares changing hands. Investing.com

London’s mood stayed subdued. The FTSE 100 dipped 0.04% to 10,235.29, pulling back from a record close the day before. Losses in mining stocks dragged down the index, despite gains in other sectors. Reuters

On Friday, RELX disclosed it acquired 306,154 shares via UBS as part of its share buyback program, with the shares designated as treasury stock. The price per share fell between 3,071 and 3,120 pence. Since January 2, the company has repurchased a total of 3,393,125 shares. TradingView

In another regulatory update Thursday, RELX filed for a block listing of 55,000 shares tied to its employee share purchase plan, with admission set for Jan. 20. These block listings relate to shares issued under employee schemes, not new capital raising. Investegate

RELX’s ADR (RELX.N) slipped to $41.63 in New York, marking a 0.55% drop from its last close.

London trading will be live on Monday, even as the U.S. market stays closed for Martin Luther King Jr. Day. That means the ADR won’t move while the London line remains active. New York Stock Exchange

That might trim cross-border flows, pushing attention back to UK-driven trading, especially for a stock that tends to move in tight increments. Traders will also watch for upcoming buyback filings and new broker research.

The bigger test lies ahead. RELX plans to release its year-end results for Dec. 31, 2025, on Feb. 12, per its financial calendar. relx.com

Investors are focused on steady growth from the group’s analytics divisions and any clues on demand for 2026. They will also scrutinize the company’s stance on cash returns — buybacks and dividends — to see if share repurchases continue at the current rate.

The risk is clear: should the February update signal weaker client spending or tighter margins, the buyback won’t prevent the stock from slipping. Currency fluctuations also play a role for firms with significant earnings outside the UK, even though their shares trade in pence on the London market.

Stock Market Today

  • Knight Therapeutics Reports Record $450.1 Million Revenue in 2025, Projects Growth for 2026
    March 20, 2026, 10:17 AM EDT. Knight Therapeutics (TSE:GUD) posted record 2025 revenue of $450.1 million, driven by acquisitions from Paladin and Sumitomo, and strong promoted product sales. Despite this, gross margin fell and the company reported a net loss influenced by inflation, inventory adjustments, and pressures in mature portfolios. Knight strengthened its balance sheet with a new US$100 million credit facility and share repurchases. For 2026, it forecasted revenues between $490 million and $510 million with an adjusted EBITDA margin around 15%, signaling confidence amid integration efforts. Analysts maintain a Buy rating with a C$7.45 price target, though AI analysis shows neutral market sentiment due to profitability and cash flow challenges.
GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results
Previous Story

GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

HSBC share price ends lower after Singapore insurance review — what to watch before markets reopen
Next Story

HSBC share price ends lower after Singapore insurance review — what to watch before markets reopen

Go toTop